SUMMARY A controlled single-blind trial has been carried out to determine the value of long-term anticholinergic therapy in duodenal ulcer. Of 106 male patients with symptomatic and radiologically proven duodenal ulcer admitted to the trial, 91 completed the study. Patients were divided randomly into three groups. They received either glycopyrronium, or 1-hyoscyamine in a sustained-release form, or inert tablets for one year.
Symptomatic improvement, both subjective and objective, occurred in approximately 80% of all patients during the year of observation; there was no significant difference between the groups.
Because anticholinergic agents reduce gastric motility and acid secretion, they have been used extensively in the treatment of peptic ulcer. In Britain the annual expenditure on such drugs is about two million pounds. Their value, however, in clinical practice is disputed and conclusions from clinical trials, many of which were uncontrolled, are conflicting.
We have attempted in this study to assess the value of two anticholinergic drugs-one a natural alkaloid, the other a synthetic compound-in the long-term treatment of patients with duodenal ulceration.
Method PATIENTS One hundred and six male patients (aged between 20 and 65) were admitted to the trial. They had had symptoms of peptic ulcer during the previous six months, and had had an ulcerated and/or deformed,duodenal cap demonstrated by radiology.
At the first interview, the nature and purpose of the trial were explained, and a standard quesReceived for publication 10 December 1969. tionnaire relating to the clinical history was completed. Those who agreed to take part in the trial and in whom there was no evidence of ischaemic heart disease, prostatic obstruction, glaucoma, or any serious disease which might have prejudiced their completion of the trial, commenced a 'run-in' period. During this time, which varied from two to six weeks, the subjects received inert tablets three times daily and antacid tablets for relief of discomfort. They were asked to record daily on a standard diary card ( Fig. 1 ) the occurrence during the day of discomfort, graded in severity from 0-3; night pain; and vomiting. Those who failed to complete the 'run-in' period satisfactorily were excluded.
TRIAL DESIGN
The active preparations were given in doses which produced tolerable side effects. The nature of treatment was therefore known to the 'doctor, but not to the patient. The trial period for each patient was one year.
Patients were allocated randomly by a system of cards in numbered envelopes, to one of three quaternary ammonium compound which is slowly absorbed and long-acting. Group B received l-hyoscyaminel. This natural alkaloid of belladonna is slowly released from a plastic matrix and therefore has a prolonged action. Group C received inert tablets which were identical in appearance to those given to groups A and B. Tablets were taken three times daily by all patients. In groups A and B, dosage was adjusted so that tolerable side effects were experienced. Dosage in group C was altered arbitrarily according to symptoms and complaint of side effects. All patients were advised to avoid articles of diet which they knew might precipitate their ulcer discomfort, to restrict consumption of alcohol and tobacco, and to avoid aspirin-containing preparations.
ASSESSMENT
Three independent methods of assessment were used.
'Egacen durules, Astra Ltd, Sweden. Symptoms Throughout the trial, patients recorded each day, on the standard diary card (Fig. 1) ,the occurrence of discomfort during the day, graded in severity from 0 (no discomfort) to 3 (severe pain most of the day), night pain, and vomiting. They were seen by one of three observers (M.K., J.R., P.B.) at four-weekly intervals at a special clinic. In addition a standard questionnaire was completed at each interview. The patient graded his ulcer symptoms for the previous four weeks as 'excellent', 'good', 'fair', 'bad', or 'terrible' . At the end of the trial the patient was asked, 'As far as your ulcer trouble is concerned, have you, during the last year, been better, worse, or the same, in comparison with the year immediately before you started coming to the clinic?' Antacid consumption All patients were given a standard antacid tablet2, and advised to take this for relief of discomfort. The number consumed each month was recorded and provided an objective index of symptoms.
Radiology
A barium meal was performed on each patient before admission to, and again at the end of, the trial. Abnormalities in the first and second parts of the duodenum were assessed and recorded independently by two radiologists (K.T.E. and G.T.D.) under the headings 'crater', 'deformity', and 'coarse folds'. Patients were included in the trial only if both radiologists recorded the presence of a crater and/or a deformity. Those with evidence of oesophageal disease, hiatus hernia, gastric ulcer, or gastric outlet obstruction, were excluded.
ACID SECRETION
Basal and maximal acid output were measured before admission to the trial and again one year later, seven days after cessation of drug administration. After a fast of at least 12 hours, basal secretion was collected for 30 minutes. Aconstantrate intravenous infusion of pentagastrin3, 6 ,ug/ kg/hr, was then given for 75 minutes and secretion collected as five 15-minute samples. Maximal acid output, expressed in m-equiv/hr, was calculated from the last three or four samples.
SIDE EFFECTS
At each clinic visit, patients were asked a standard series of questions concerning side effects referable to mouth, eyes, bladder, bowel, and heartbeat. ' (Fig. 2) . There was no significant difference between the three groups. Furthermore, the distributions for the total number of days on which each of the four MEDIAN:46 grades (0-3) of discomfort occurred were similar for the three groups. There was no significant difference between the groups either in the total number of nights of pain experienced during the trial (Fig. 3) or in the total number of days on m | which vomiting occurred (Fig. 4 ). The total score for each patient was calculated by addition of his 13 monthly scores, which for any month rangedfrom I ('excellent') to 5 ('terrible'). (Fig. 6 ).
Correlations between Methods of Symptom Assessment
Comparison of the various methods of assessment used are shown in In the dosages used, both drugs produced significant dryness of the mouth and blurring of vision but neither drug significantly affected micturition or heart beat. There was a suggestion (p < 01) that more patients on glycopyrronium suffered from constipation, but otherwise the side effects were similar with the two anticholinergic drugs.
Loss of libido was a common complaint, but sexual performance was not adversely affected by either glycopyrronium or 1-hyoscyamine.
COMPLICATIONS
The only complication occurred in one patient from group B (1-hyoscyamine) who developed melaena three days before he completed the trial. Surgery was performed shortly after the trial in four patients with severe symptoms. Two of these were from group A (glycopyrronium) and two from group C (placebo). 6-7 ± 5 7 8-3 ± 4.9 41-6 + 11-8 41-1 + 12-2 C (placebo) 32 6-9 + 8-4 7.0 + 6-1 39-1 ± 10-1 39-2 + 10-7 Friedlander (1954) , in a controlled trial in patients with duodenal ulcer, found that methantheline produced initial symptomatic benefit compared with a placebo, but this was not maintained. Later Ruffin and Cayer (1962) , in a large double-blind study involving 1,034 patients with peptic ulcer, found that 48 % of patients on placebo, 53% of those on atropine, and 74% of those on synthetic anticholinergics improved. No information, however, is given on the comparability of groups. A similar criticism applies to the trials described by Sun (1962) , who assessed progress on the basis of recurrences, the latter being defined as 'ulcer-like symptoms with or without crater, deformity, irritability of duodenum, or ... painless bleeding'. Six of 20 patients in the placebo group bled, as opposed to one of 25 patients given tricycamol. The overall recurrence rates were 45 % and 8 % respectively, a significant difference. In a later trial (Sun, 1964) , glycopyrronium was used, and it was found that ulcer-like symptoms recurred in 15 % of patients on glycopyrronium, but, on this occasion, in 71 % of those on placebo. A further trial comparing glycopyrronium and placebo in duodenal ulcer was carried out by Trevino, Anderson, Davey, and Henley (1967) . Forty-six patients with proven duodenal ulcer were followed for between 18 and 27 months and glycopyrronium was not significantly superior to the placebo.
Poldine methosulphate', an anticholinergic 'Nacton, Bencard.
agent which, like glycopyrronium, has a quaternary ammonium structure, was not found to be superior to a placebo when given for nine months to patients with duodenal ulcer (Melrose and Pinkerton, 1961) . Lennard-Jones (1961) came to the same conclusion in a single-blind crossover study of 11 patients, all of whom were followed for two consecutive three-month periods. Similarly Hunt and Wales (1966) Loss of working time has also been used as an index of progress (Lennard-Jones, 1961; Hunt and Wales, 1966) . We abandoned this criterion when we found that the reasons for loss of work could not be assessed; several patients were unemployed throughout the trial.
Complication rate provides an objective guide to the course of duodenal ulcer (Sun, 1962 and 1964) but in our series of 91 patients followed for a year, only one complication occurred and the number who required surgery was too small to justify any comparison between the groups. These results are in marked contrast to those of Sun, and may reflect differences in the populations of patients studied.
For these reasons our assessment was based entirely upon an objective analysis of symptoms. The high degree of correlation between antacid consumption, monthly assessments, and symptom score (from diary cards) supports the validity of our method of assessment.
A double-blind trial was considered to be impracticable because the active drugs were given in maximum tolerable doses. In retrospect, a crossover trial might have been preferable. Such a design was not chosen because of the report (Hunt and Wales, 1966 ) that prolonged continuous administration of poldine to patients with peptic ulcer reduced acid secretion for considerable periods after drug withdrawal. In fact, there was no evidence in our patients that basal or maximal acid output were reduced beyond the period of drug administration though both drugs used in this trial have been shown to inhibit gastric acid secretion as provoked by a variety of stimuli (Moeller, 1962; Posey, 1962; Sun, 1962; Abbott, Sourial, Krieger, and Levey, 1962; Barman and Larson, 1963; Dotevall, Schroder, and Walan, 1965; Christianson and Rodbro, 1967; Kaye, Rhodes, and Sweetnam, 1968) . Indeed, basal output, measured seven days after treatment was stopped, was increased in patients who had received anticholinergic drugs, significantly so in those given glycopyrronium. It is possible that this increase was transient, and in the nature of a 'rebound' phenomenon but since further secretory studies were not done this is speculative.
Although differences between the three groups were statistically insignificant, the median values for all methods of symptom assessment suggest that patients given glycopyrronium or l-hyoscyamine fared slightly better than those who received placebo. It seems likely, however, that this small difference is clinically unimportant. In view of the side effects of these drugs, we would conclude that their long-term prophylactic use in patients with duodenal ulcer is not justified.
That a substantial proportion of patients in this trial showed both subjective and objective evidence of improvement during the year of observation is not altogether unexpected. If it is true that around 10 % of the population are at some time of their lives afflicted byduodenal ulcer (Watkinson, 1960) then it seems likely that relatively few suffer severely for a long time, develop complications, or require surgery. The need for adequate controls in trials of any form of treatment for this condition cannot be overemphasized.
